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Abstracts
e64 -expression with myeloma stage, response rate post-treatment, and
progression-free survival (PFS) were compared using bivariate and
multivariate statistics. Results: 762 patients were included in the
analysis. The median age at diagnosis was 63 (range 27-93) and
50% were male. Mean LAT1 expression was 3.00 logs ( 0.95);
30% were considered to have high LAT1 expression. High LAT1
was observed in 40% of patients with Stage III disease, compared to
27% of those with Stage I or II disease (p < .001) 296 patients
underwent ASCT during first-line treatment with 39% having a
complete response (CR). 49% of those with high LAT1 obtained a
CR compared to 35% of those without (p ¼ .030). 16% of the 466
patients who did not undergo ASCT also obtained a CR. 21% of
those with high LAT1 obtained a CR compared to 14% of those
without, which was not statistically significant. Overall, high LAT1
expression was associated with a 34% increase risk for PFS (aHR
1.34; 95% CI 1.07-1.69; p ¼ .012) after controlling for ASCT,
CR, and ISS stage. However, the risk was mitigated in patients
undergoing ASCT. For those with high LAT1, receiving an ASCT
resulted in a 47% decrease in risk (aHR 0.53; 95% CI 0.37-0.74; p
< .001) and PFS was similar to those with normal LAT1 expres-
sion. Discussion: Melphalan-based ASCT may mitigate the higher
risk associated with high LAT1 expression at diagnosis of multiple
myeloma. While ASCT is generally recommended for all eligible
patients with multiple myeloma, those with high LAT1 may receive
an even larger benefit.
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Multiple myeloma (MM) is characterized by high genetic het-
erogeneity, which in turn affects not only the development of the
disease but also the therapeutic response. To further characterise the
genetic heterogeneity in MM, we applied a novel approach of next-
generation optical mapping to study a genomic architecture of MM
cells. We analysed samples of bone marrow from two patients with
newly diagnosed MM using optical mapping together with standard17th International Myeloma Workshop, September 12-15, 2019Methods (karyotype, FISH, and arrayCGH) and compared the
Results of these approaches. For optical mapping, high-molecular
weight DNA was isolated from sorted MM cells, labelled by DLS
chemistry and visualised on Saphyr system (BioNano Genomics).
The optical genome maps (480 Gbp, coverage 124X) were aligned
to a human reference genome (GRCh38) and the detected struc-
tural variants (SVs) were compared against the database of healthy
controls; only rare de novo variants were analysed. In Patient 1
(male, 77 years, MM IgG kappa, stage IIIA (Durie-Salmon, DS),
International Staging System (ISS) 2, revised ISS (R-ISS) 2)
numerous genetic aberrations were detected by both optical map-
ping and arrayCGH (trisomy 4, 11, 18, 19, 21, monosomy 13 and
tetrasomy 15). Optical mapping revealed additional 47 deletions, 16
insertions, 14 inversions, 4 duplications and 4 translocations. All
translocations were within unusual chromosomes 3 and 6. We also
identified 587 bp insertion in 17p13 chromosome and 8.1 kbp
deletion in 18q21 chromosome, both regions affecting the activa-
tion of cancer genes tumor suppressors and oncogenes. Additionally,
several large SVs were located on chromosome 3, including dupli-
cation, inversion, intra- and inter-chromosomal translocations
t(3;6). In Patient 2 (male, 74 years, MM IgA kappa, st. IIIA (DS),
ISS 2, R-ISS 2), both optical mapping and arrayCGH detected
trisomy 3, 5, 9, 11, 15, 18, 19 and tetrasomy 21. Optical mapping
revealed additional 35 deletions, 22 insertions, 11 inversions, 2
duplications and 8 intrachromosomal translocations affecting
chromosomes 3, 4, 14, and 18. Although no IGH locus rear-
rangements were detected by standard methods, monosomy on
chromosome 14 and 20.5 kbp deletion were found within IGH
locus by optical mapping. As conclusion, a large number of addi-
tional novel genomic rearrangements was detected in MM using
next-generation mapping technology, showing a high potential of
optical maps for refinement of genomic variability in MM. The
study on larger patient cohort and longer follow-up of patients may
identify structural variants associated with the clinical course and
therapy response. Support: research grant Celgene, MZ CR VES16-
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Gene fusions are an important class of genetic variation relevant
across cancer types. We detected gene fusion events from a cohort of
742 patients from the Multiple Myeloma Research Foundation
CoMMpass Dataset, combining sequencing data from RNA and
DNA with clinical information to form a landscape of fusion events.
